Comparative Pharmacology
Head-to-head clinical analysis: BUTRANS versus KADIAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTRANS versus KADIAN.
BUTRANS vs KADIAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
None Documented
None Documented
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic